Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Adavosertib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 12 Aug 2019 Planned number of patients changed from 36 to 114.
- 26 Apr 2019 Planned primary completion date changed from 15 Feb 2019 to 28 Feb 2020.
- 20 Sep 2018 Planned primary completion date changed from 15 Aug 2018 to 15 Feb 2019.